Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$58.71 -0.26 (-0.44 %)
(As of 01/16/2018 10:36 AM ET)
Previous Close$58.97
Today's Range$58.26 - $59.21
52-Week Range$46.42 - $63.40
Volume707,300 shs
Average Volume896,700 shs
Market Capitalization$8.99 billion
P/E Ratio-52.89
Dividend YieldN/A
Beta2.13

About Alkermes (NASDAQ:ALKS)

Alkermes logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone+353-1-7728000

Debt

Debt-to-Equity Ratio0.23%
Current Ratio3.05%
Quick Ratio2.72%

Price-To-Earnings

Trailing P/E Ratio-52.8918918918919
Forward P/E Ratio-99.51
P/E GrowthN/A

Sales & Book Value

Annual Sales$745.69 million
Price / Sales12.11
Cash FlowN/A
Price / CashN/A
Book Value$7.96 per share
Price / Book7.38

Profitability

Trailing EPS($1.11)
Net Income$-208,440,000.00
Net Margins-20.12%
Return on Equity-7.27%
Return on Assets-5.05%

Miscellaneous

Employees1,750
Outstanding Shares153,780,000

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) released its earnings results on Thursday, October, 26th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes's quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.09) EPS. View Alkermes' Earnings History.

When will Alkermes make its next earnings announcement?

Alkermes is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY17 earnings guidance on Wednesday, January, 10th. The company provided earnings per share guidance of $0.03-0.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.12. The company issued revenue guidance of $870-900 million, compared to the consensus revenue estimate of $882.79 million.

Where is Alkermes' stock going? Where will Alkermes' stock price be in 2018?

10 analysts have issued 1 year price objectives for Alkermes' stock. Their predictions range from $50.00 to $81.00. On average, they expect Alkermes' stock price to reach $64.50 in the next year. View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:

  • 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada are primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being- FDA review of the ALKS 5461 new drug application (NDA) for treatment of major depressive disorder, the phase III data readout for ALKS 3831 in schizophrenia, submission of the ALKS 8700 NDA and phase I data read-out for ALKS 4230. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Moreover, Alkermes’ shares have underperformed the industry year to date. Estimates have remained stable ahead of the Q4 earnings results." (1/8/2018)
  • 2. Cowen Inc analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in the month of December. As of December 15th, there was short interest totalling 11,545,345 shares, an increase of 23.8% from the November 30th total of 9,327,711 shares. Based on an average daily volume of 1,264,244 shares, the short-interest ratio is currently 9.1 days. Currently, 7.6% of the shares of the company are sold short.

Who are some of Alkermes' key competitors?

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer (Age 55)
  • Shane M. Cooke, President (Age 54)
  • James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer (Age 49)
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary (Age 58)
  • Elliot W. Ehrich M.D., Executive Vice President - Science and Therapeutics (Age 57)
  • Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer (Age 48)
  • David Joseph Gaffin, Senior Vice President, Chief Legal Officer (Age 45)

Who owns Alkermes stock?

Alkermes' stock is owned by many different of retail and institutional investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (11.35%), Nisa Investment Advisors LLC (0.03%) and Daiwa SB Investments Ltd. (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Who bought Alkermes stock? Who is buying Alkermes stock?

Alkermes' stock was purchased by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Alkermes.

How do I buy Alkermes stock?

Shares of Alkermes can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of Alkermes stock can currently be purchased for approximately $58.71.

How big of a company is Alkermes?

Alkermes has a market capitalization of $8.99 billion and generates $745.69 million in revenue each year. The company earns $-208,440,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Alkermes employs 1,750 workers across the globe.

How can I contact Alkermes?

Alkermes' mailing address is Connaught HSE, 1 Burlington Road, DUBLIN, MA 00000, Ireland. The company can be reached via phone at +353-1-7728000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  341 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alkermes (NASDAQ:ALKS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.56
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $64.50$64.50$63.25$64.00
Price Target Upside: 28.08% upside28.08% upside25.77% upside10.40% upside

Alkermes (NASDAQ:ALKS) Consensus Price Target History

Price Target History for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017Credit Suisse GroupSet Price TargetBuy$66.00MediumView Rating Details
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
10/26/2017BarclaysSet Price TargetHold$50.00N/AView Rating Details
10/26/2017CitigroupSet Price TargetHold$62.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$81.00N/AView Rating Details
8/25/2017Jefferies GroupSet Price TargetBuy$69.00LowView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
4/28/2017CowenReiterated RatingBuyLowView Rating Details
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00LowView Rating Details
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00MediumView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$57.00 -> $35.00N/AView Rating Details
1/21/2016GuggenheimReiterated RatingHoldN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Alkermes (NASDAQ:ALKS) Earnings History and Estimates Chart

Earnings by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.13N/AView Earnings Details
10/26/20179/30/2017($0.01)$0.03$231.29 million$217.40 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.15)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.14)($0.14)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.15)($0.15)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.14)($0.07)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.10)($0.09)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.11)($0.11)ViewN/AView Earnings Details
5/21/2009Q1 2009($0.13)($0.14)ViewN/AView Earnings Details
2/5/2009Q4 2008$1.20$1.18ViewN/AView Earnings Details
11/6/2008Q3 2008($0.01)$0.02ViewN/AView Earnings Details
8/7/2008Q2 2008$0.17$0.31ViewN/AView Earnings Details
5/22/2008Q1 2008$0.01($0.07)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.01)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alkermes (NASDAQ:ALKS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181$0.07$0.07$0.07
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.08)($0.08)($0.08)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes (NASDAQ:ALKS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 99.66%
Insider Trades by Quarter for Alkermes (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Iain Michael BrownCAOSell10,652$54.81$583,836.1216,943View SEC Filing  
1/2/2018Paul J MitchellDirectorSell1,000$54.99$54,990.009,000View SEC Filing  
12/29/2017Iain Michael BrownSVPSell10,652$54.81$583,836.12View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.80View SEC Filing  
12/1/2017Paul J MitchellDirectorSell1,000$51.98$51,980.009,000View SEC Filing  
11/29/2017James M FratesSVPSell20,932$50.51$1,057,275.32164,971View SEC Filing  
11/8/2017James M. FratesSVPSell20,932$47.58$995,944.56View SEC Filing  
11/2/2017Richard F PopsDirectorSell50,000$48.87$2,443,500.00View SEC Filing  
11/1/2017Michael J LandineSVPSell15,000$48.71$730,650.00178,693View SEC Filing  
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.1470,455View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.009,500View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.009,500View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.009,500View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.0084,708View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.009,500View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00649,137View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00167,370View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00680,406View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00172,370View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00655,406View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.0078,448View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.0065,071View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.0069,904View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.009,500View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.0072,148View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.3074,948View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.0072,048View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.0072,048View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.0066,071View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00144,053View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.007,156View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.0073,068View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.009,500View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.0049,657View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.009,500View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.5662,640View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.6934,662View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.5064,494View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.0060,140View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.6536,615View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.0066,487View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.0011,156View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.0027,207View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.009,500View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.7037,277View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.0057,640View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00127,342View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.4564,623View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.8543,687View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.0038,687View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00165,659View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00638,962View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00638,962View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.0010,000View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.0046,477View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.0050,311View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.4422,816View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.0055,311View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.9225,696View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.0010,000View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.0010,000View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.0546,111View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.0010,000View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.0010,000View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.0010,000View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75159,419View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50595,247View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.3651,822View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.6852,642View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00601,497View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.0010,000View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00601,497View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00581,307View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.0010,000View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.0015,000View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.008,000View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.0035,156View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.0019,564View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.0050,240View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00141,324View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00553,497View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.0019,564View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00141,324View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00553,497View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.0037,156View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.0050,240View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.0019,964View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.0039,156View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.7838,689View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.0050,240View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.0051,357View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.0041,156View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.0040,640View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00138,680View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00542,917View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.0048,713View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00138,680View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00542,917View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.0043,156View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.0040,640View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.2220,992View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.0054,192View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.141,321View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.0023,370View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.0042,904View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.3020,992View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.0090,281View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.0053,756View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.008,000View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.0036,644View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.008,000View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.0036,644View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.001,600View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.0093,644View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.1016,579View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.008,000View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.9816,579View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.2516,579View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.0048,301View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.0093,644View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alkermes (NASDAQ ALKS) News Headlines

Source:
DateHeadline
Alkermes (ALKS) Issues FY17 Earnings GuidanceAlkermes (ALKS) Issues FY17 Earnings Guidance
www.americanbankingnews.com - January 10 at 9:04 AM
'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says
finance.yahoo.com - January 9 at 3:26 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018
finance.yahoo.com - January 9 at 3:26 PM
Alkermes Is Getting Ready for a RallyAlkermes Is Getting Ready for a Rally
finance.yahoo.com - January 9 at 3:26 PM
Alkermes Plc (ALKS) Receives Average Recommendation of "Hold" from AnalystsAlkermes Plc (ALKS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 9 at 11:34 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKSEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKS
finance.yahoo.com - January 9 at 9:46 AM
Best days are still ahead for top opioid addiction treatment Vivitrol, CEO says'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says
finance.yahoo.com - January 9 at 9:46 AM
'Best days are still ahead' for top opioid addiction trea...'Best days are still ahead' for top opioid addiction trea...
finance.yahoo.com - January 9 at 9:46 AM
Alkermes CEO: 'Best days are still ahead' for opioid addi...Alkermes CEO: 'Best days are still ahead' for opioid addi...
finance.yahoo.com - January 9 at 9:46 AM
Alkermes: Cramers Top TakeawaysAlkermes: Cramer's Top Takeaways
finance.yahoo.com - January 9 at 9:46 AM
Alkermes Plc Forecasted to Post Q1 2018 Earnings of ($0.22) Per Share (ALKS)Alkermes Plc Forecasted to Post Q1 2018 Earnings of ($0.22) Per Share (ALKS)
www.americanbankingnews.com - January 8 at 5:36 AM
Primecap Managers Acing Index Raise Bet on AlkermesPrimecap Managers Acing Index Raise Bet on Alkermes
finance.yahoo.com - January 6 at 8:31 AM
Analysts Offer Predictions for Alkermes Plcs FY2019 Earnings (ALKS)Analysts Offer Predictions for Alkermes Plc's FY2019 Earnings (ALKS)
www.americanbankingnews.com - January 5 at 5:26 PM
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline: January 22, 2018SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline: January 22, 2018
finance.yahoo.com - January 5 at 3:28 PM
The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - January 5 at 3:28 PM
Alkermes Plc (ALKS) Expected to Announce Quarterly Sales of $247.52 MillionAlkermes Plc (ALKS) Expected to Announce Quarterly Sales of $247.52 Million
www.americanbankingnews.com - January 5 at 12:24 PM
[$$] Primecap: Two Stocks Its Buying, One Its Selling[$$] Primecap: Two Stocks It's Buying, One It's Selling
finance.yahoo.com - January 5 at 9:00 AM
Insider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of StockInsider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of Stock
www.americanbankingnews.com - January 3 at 7:28 PM
Alkermes Corporate Presentation to be Webcast at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)Alkermes' Corporate Presentation to be Webcast at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 3 at 3:26 PM
$0.17 EPS Expected for Alkermes Plc (ALKS) This Quarter$0.17 EPS Expected for Alkermes Plc (ALKS) This Quarter
www.americanbankingnews.com - January 3 at 9:28 AM
Iain Michael Brown Sells 10,652 Shares of Alkermes Plc (ALKS) StockIain Michael Brown Sells 10,652 Shares of Alkermes Plc (ALKS) Stock
www.americanbankingnews.com - January 3 at 12:30 AM
Alkermes Corporate Presentation to be Webcast at the 36th Annual J.P. Morgan Healthcare ConferenceAlkermes' Corporate Presentation to be Webcast at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:36 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline: January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline: January 22, 2018
finance.yahoo.com - December 29 at 11:01 AM
Alkermes Plc (ALKS) Sees Large Increase in Short InterestAlkermes Plc (ALKS) Sees Large Increase in Short Interest
www.americanbankingnews.com - December 29 at 3:04 AM
Does Alkermes plc’s (NASDAQ:ALKS) Latest Financial Perfomance Look Strong?Does Alkermes plc’s (NASDAQ:ALKS) Latest Financial Perfomance Look Strong?
finance.yahoo.com - December 28 at 9:14 AM
BidaskClub Upgrades Alkermes (ALKS) to "Hold"BidaskClub Upgrades Alkermes (ALKS) to "Hold"
www.americanbankingnews.com - December 27 at 9:44 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKSINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS
finance.yahoo.com - December 27 at 1:42 PM
The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a ... - Business Wire (press release)The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a ... - Business Wire (press release)
www.businesswire.com - December 22 at 8:43 AM
Alkermes Plc (ALKS) SVP Laurie Keating Sells 6,249 SharesAlkermes Plc (ALKS) SVP Laurie Keating Sells 6,249 Shares
www.americanbankingnews.com - December 21 at 5:24 PM
The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 21 at 3:28 PM
ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 20 at 3:25 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 19 at 3:26 PM
The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead ... - Business Wire (press release)The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead ... - Business Wire (press release)
www.businesswire.com - December 19 at 8:59 AM
Alkermes Plc (ALKS) Expected to Post Quarterly Sales of $239.12 MillionAlkermes Plc (ALKS) Expected to Post Quarterly Sales of $239.12 Million
www.americanbankingnews.com - December 19 at 5:52 AM
The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018The Klein Law Firm Announces a Class Action Commenced on Behalf of Alkermes plc Shareholders and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 18 at 3:26 PM
Zacks: Analysts Expect Alkermes Plc (ALKS) Will Announce Earnings of $0.17 Per ShareZacks: Analysts Expect Alkermes Plc (ALKS) Will Announce Earnings of $0.17 Per Share
www.americanbankingnews.com - December 17 at 5:32 PM
ALKS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Alkermes plc ... - Business Wire (press release)ALKS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Alkermes plc ... - Business Wire (press release)
www.businesswire.com - December 15 at 3:29 PM
Alkermes PLC (ALKS) Given Average Rating of "Hold" by AnalystsAlkermes PLC (ALKS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 15 at 12:28 PM
Alkermes PLC (ALKS) Receives Consensus Recommendation of "Hold" from BrokeragesAlkermes PLC (ALKS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 15 at 12:26 PM
Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Alkermes plc (ALKS)Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Alkermes plc (ALKS)
finance.yahoo.com - December 12 at 3:26 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - December 12 at 3:26 PM
ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 12 at 8:45 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - December 11 at 3:25 PM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alkermes plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - December 11 at 3:25 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline – ALKSSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline – ALKS
finance.yahoo.com - December 9 at 9:01 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action ... - GlobeNewswire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action ... - GlobeNewswire (press release)
globenewswire.com - December 7 at 3:28 PM
Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - December 7 at 3:28 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKSINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alkermes plc of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 – ALKS
finance.yahoo.com - December 7 at 3:28 PM
Surging Earnings Estimates Signal Good News for Alkermes (ALKS)Surging Earnings Estimates Signal Good News for Alkermes (ALKS)
www.zacks.com - December 7 at 8:49 AM
Robbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Alkermes plc (ALKS) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 7 at 8:49 AM

SEC Filings

Alkermes (NASDAQ:ALKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alkermes (NASDAQ ALKS) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.